LLY Stock - Eli Lilly and Company
Unlock GoAI Insights for LLY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $45.04B | $34.12B | $28.54B | $28.32B | $24.54B |
| Gross Profit | $36.62B | $27.04B | $21.91B | $21.01B | $19.06B |
| Gross Margin | 81.3% | 79.2% | 76.8% | 74.2% | 77.7% |
| Operating Income | $17.50B | $10.79B | $8.65B | $7.93B | $7.21B |
| Net Income | $10.59B | $5.24B | $6.24B | $5.58B | $6.19B |
| Net Margin | 23.5% | 15.4% | 21.9% | 19.7% | 25.2% |
| EPS | $11.76 | $5.83 | $6.57 | $5.85 | $6.47 |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 16th 2025 | Daiwa Securities | Upgrade | Buy | $1230 |
| December 15th 2025 | Goldman | Reiterated | Buy | $1145← $951 |
| December 15th 2025 | BofA Securities | Reiterated | Buy | $1268← $1286 |
| November 13th 2025 | Scotiabank | Initiation | Sector Outperform | $1165 |
| November 10th 2025 | Leerink Partners | Upgrade | Outperform | $1104 |
| October 20th 2025 | BMO Capital Markets | Reiterated | Outperform | $930← $840 |
| October 14th 2025 | Erste Group | Upgrade | Buy | - |
| September 17th 2025 | Berenberg | Downgrade | Hold | $830 |
| August 27th 2025 | HSBC Securities | Upgrade | Hold | $700 |
| August 18th 2025 | Daiwa Securities | Downgrade | Neutral | $700 |
| August 7th 2025 | Leerink Partners | Downgrade | Market Perform | $715 |
| June 5th 2025 | Erste Group | Downgrade | Hold | - |
| April 28th 2025 | HSBC Securities | Downgrade | Reduce | $700← $1150 |
| April 22nd 2025 | Cantor Fitzgerald | Initiation | Overweight | $975 |
| December 10th 2024 | BofA Securities | Resumed | Buy | $997 |
Earnings History & Surprises
LLYEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 5, 2026 | $7.48 | — | — | — |
Q4 2025 | Oct 30, 2025 | $5.69 | $7.02 | +23.4% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $5.60 | $6.31 | +12.7% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $3.26 | $3.34 | +2.5% | ✓ BEAT |
Q1 2025 | Feb 6, 2025 | $5.03 | $5.32 | +5.8% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $1.47 | $1.18 | -19.7% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $2.60 | $3.92 | +50.8% | ✓ BEAT |
Q2 2024 | Apr 30, 2024 | $2.46 | $2.58 | +4.9% | ✓ BEAT |
Q1 2024 | Feb 6, 2024 | $2.22 | $2.49 | +12.2% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-0.08 | $0.10 | +225.0% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $1.98 | $2.11 | +6.6% | ✓ BEAT |
Q2 2023 | Apr 27, 2023 | $1.73 | $1.62 | -6.4% | ✗ MISS |
Q1 2023 | Feb 2, 2023 | $1.78 | $2.09 | +17.4% | ✓ BEAT |
Q4 2022 | Nov 1, 2022 | $1.92 | $1.98 | +3.1% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $1.69 | $1.25 | -26.0% | ✗ MISS |
Q2 2022 | Apr 28, 2022 | $2.32 | $2.62 | +12.9% | ✓ BEAT |
Q1 2022 | Feb 3, 2022 | $2.51 | $2.49 | -0.8% | ✗ MISS |
Q4 2021 | Oct 26, 2021 | $1.98 | $1.94 | -2.0% | ✗ MISS |
Q3 2021 | Aug 3, 2021 | $1.89 | $1.87 | -1.1% | ✗ MISS |
Latest News
Shars of drug companies are higher after announcing deals with President Trump for lower drug prices.
📈 PositivePresident Trump Says The 3 Of The 17 Pharmaceutical Companies Who Have Not Agreed Are Coming In Next Week
➖ NeutralTrump Administration Proposes Rule Banning Medicaid And CHIP From Paying For Gender Affirming Care
➖ NeutralEli Lilly Announces Topline Results From ATTAIN-MAINTAIN Trial; Orforglipron Meets Primary And Key Secondary Endpoints For Weight Maintenance At 52 Weeks
📈 Positive'Eli Lilly & Co. Cuts Price Of Popular Diabetes And Weight-Loss Drugs In Canada' - The Globe And Mail
📉 NegativeEli Lilly shares are trading higher after Bank of America reiterated a Buy rating, citing continued upside potential.
📈 PositiveB of A Securities Maintains Buy on Eli Lilly, Lowers Price Target to $1268
➖ NeutralEli Lilly Reports Inluriyo Shows Major Survival Gains In ESR1-Mutated Breast Cancer And Strong Combo Benefits With Abemaciclib In Phase 3 EMBER-3 Study; Results Published In Annals of Oncology Ahead Of SABCS Presentation
📈 PositiveReuters Reported FDA Presses Reviewers To Accelerate Evaluation Of Eli Lilly's Weight-Loss Pill; Decision Could Come By March 28 If New Timeline Adopted, Citing Internal Documents
📈 PositiveEli Lilly shares are trading higher after the company reported its Phase 3 TRIUMPH-4 trial of retatrutide met all primary and key secondary endpoints, showing significant weight loss and improved pain and physical function.
📈 PositiveEli Lilly obesity drug results in weight loss — and reduced knee pain — in trial
📈 PositiveEli Lilly Shared Topline Results From the Phase 3 TRIUMPH-4 Trial of Two Highest Investigational Doses of Retatrutide in Adults With Obesity or Overweight and Knee Osteoarthritis, and Without Diabetes; Retatrutide Lowered Weight by Up to an Average of 28.7% and Reduced Pain by Up to an Average of 4.5 Points
📈 PositiveEli Lilly ends in green after nine consecutive sessions of decline
📈 PositiveWells Fargo Maintains Overweight on Eli Lilly, Raises Price Target to $1200
📈 PositiveEli Lilly acquisition rumors reportedly fuel Abivax rally
📈 PositiveReuters Issues Correction: U.S. FDA Says "Doing A Thorough Investigation, Across Multiple Age Groups, Of Deaths Potentially Related To Covid Vaccines"
📉 NegativeEli Lilly Plans To Invest More Than $6B In New Manufacturing Facility In Huntsville, Alabama, Creating 450 High-Value Jobs And 3,000 Construction Jobs; Completion Expected In 2032
📈 PositiveEli Lilly And Adverum Announce Expiration Of Tender Offer By Lilly Subsidiary To Acquire All Outstanding Adverum Shares For $3.56 Cash Plus Up To $8.91 Per Share In Contingent Value Rights, As Scheduled On December 8
📈 PositiveEli Lilly's Jaypirca Cuts Risk Of CLL Progression Or Death By 80% In Phase 3 Trial
📈 PositiveLilly On Sunday, Announced Jaypirca Met Its Primary Endpoint In Phase 3 CLL/SLL Study Vs Imbruvica
📈 PositiveFrequently Asked Questions about LLY
What is LLY's current stock price?
What is the analyst price target for LLY?
What sector is Eli Lilly and Company in?
What is LLY's market cap?
Does LLY pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to LLY for comparison